Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 1
2019 1
2020 2
2021 2
2022 6
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study.
Lopetuso LR, Laterza L, Petito V, Pecere S, Quaranta G, Del Chierico F, Puca P, Schiavoni E, Napolitano D, Poscia A, Ianiro G, Pugliese D, Putignani L, Sanguinetti M, Armuzzi A, Masucci L, Gasbarrini A, Cammarota G, Scaldaferri F. Lopetuso LR, et al. Among authors: schiavoni e. Microorganisms. 2023 Oct 11;11(10):2536. doi: 10.3390/microorganisms11102536. Microorganisms. 2023. PMID: 37894194 Free PMC article.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A, Zippi M, Napolitano D, Schiavoni E, Pugliese D, Scaldaferri F, Costa F, Marzo M, Serio M, Scarcelli A, Bolognini L, Bendia E, Maconi G, Cannatelli R, Piergallini S, Bodini G, Calabrese F, Ferronato A, Pranzo G, Elisei W, Monterubbianesi R, Faggiani R, Rodinò S, Sebkova L, Grossi L, Gaiani F, Dè Angelis G, Lorenzetti R, Allegretta L, Cazzato AI, Scorza S, Della Valle N, Sacco R, Forti G, Colucci R, Tonti P, Neve V, Rocco G, Sacchi C, Zampaletta C, Pagnini C, Graziani MG, Di Paolo MC, Onidi FM, Usai Satta P, Picchio M, Papa A. Tursi A, et al. Among authors: schiavoni e. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1649-1656. doi: 10.1080/14656566.2023.2230126. Epub 2023 Jun 28. Expert Opin Pharmacother. 2023. PMID: 37358928
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission.
Parisio L, Settanni CR, Varca S, Laterza L, Lopetuso LR, Napolitano D, Schiavoni E, Turchini L, Fanali C, Alfieri N, Pizzoferrato M, Papa A, Pafundi PC, Armuzzi A, Gasbarrini A, Pugliese D, Scaldaferri F. Parisio L, et al. Among authors: schiavoni e. J Gastrointestin Liver Dis. 2023 Dec 22;32(4):452-459. doi: 10.15403/jgld-5084. J Gastrointestin Liver Dis. 2023. PMID: 38147610 Free article.
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, Scarcelli A, Pagnini C, Graziani MG, Di Paolo MC, Pranzo G, Luppino I, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Ferronato A, Perini B, Savarino E, Onidi FM, Binaghi L, Usai Satta P, Schiavoni E, Napolitano D, Scaldaferri F, Pugliese D, Pica R, Cocco A, Zippi M, Rodino S, Sebkova L, Rocco G, Sacchi C, Zampaletta C, Gaiani F, De Angelis G, Kayali S, Fanigliulo L, Lorenzetti R, Allegretta L, Scorza S, Cuomo A, Donnarumma L, Della Valle N, Sacco R, Forti G, Antonelli E, Bassotti G, Iannelli C, Luzza F, Aragona G, Perazzo P, Lauria A, Piergallini S, Colucci R, Bianco MA, Meucci C, Giorgetti G, Clemente V, Fiorella S, Penna A, De Medici A, Picchio M, Papa A. Mocci G, et al. Among authors: schiavoni e. Expert Opin Biol Ther. 2023 Mar;23(3):293-304. doi: 10.1080/14712598.2023.2185510. Epub 2023 Mar 2. Expert Opin Biol Ther. 2023. PMID: 36843568
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center.
Scaldaferri F, D'Onofrio AM, Calia R, Di Vincenzo F, Ferrajoli GF, Petito V, Maggio E, Pafundi PC, Napolitano D, Masi L, Schiavoni E, Fanali C, Puca P, Turchini L, Lopetuso LR, Del Chierico F, Putignani L, Gasbarrini A, Camardese AG. Scaldaferri F, et al. Among authors: schiavoni e. Inflamm Bowel Dis. 2023 Nov 2;29(11):1805-1818. doi: 10.1093/ibd/izad091. Inflamm Bowel Dis. 2023. PMID: 37280117 Free PMC article.
Clinical research coordinators: Key components of an efficient clinical trial unit.
Mora V, Colantuono S, Fanali C, Leonetti A, Wlderk G, Pirro MA, Calà Palmarino FM, Savini R, Ianiro G, Gasbarrini A; SC&RN group. Mora V, et al. Contemp Clin Trials Commun. 2023 Jan 21;32:101057. doi: 10.1016/j.conctc.2023.101057. eCollection 2023 Apr. Contemp Clin Trials Commun. 2023. PMID: 36747989 Free PMC article. No abstract available.
The inflammatory bowel disease care manager: Italian state of the art.
Napolitano D, Vincenzo FD, Orgiana N, Schiavoni E, Germini F, Pugliese D, Scaldaferri F; IBD UNIT-CEMAD. Napolitano D, et al. Among authors: schiavoni e. Ann Gastroenterol. 2024 Jan-Feb;37(1):37-45. doi: 10.20524/aog.2023.0852. Epub 2023 Dec 23. Ann Gastroenterol. 2024. PMID: 38223251 Free PMC article.
22 results